Schedule an Appointment Pay Bill View My Results
Banner Image

Test Directory

Browse A-Z History Resources
Test Directory » AD Detect ® Phosphorylated TAU181 (P-TAU181)

AD Detect ® Phosphorylated TAU181 (P-TAU181)

Order Code: ADP181

Test Summary

Intended to be used as an aid in the initial assessment for Alzheimer's disease and other causes of cognitive decline in adult patients aged 55 years and older, presenting with signs, symptoms, or complaints of cognitive decline. The result should be interpreted in conjunction with other clinical information. A negative test result is consistent with a negative amyloid positron emission tomography (PET) scan result and reduced likelihood that a patient's cognitive impairment is due to amyloid pathology. These patients should be investigated for other causes of cognitive decline.

A Positive test result may not be consistent with a positive amyloid PET scan result. Patients with an initial positive result should be further investigated to determine whether the amyloid pathology can be a cause of cognitive impairment.

Aliases

  • PhosphoTau-181P

Specimen Collection

Special Instructions

N/A

Preferred Specimen

1 mL  plasma collected in an EDTA (lavender-top) tube. Room Temperature

Minimum Volume

0.5 mL

Instructions

N/A

Patient Preparation

Dietary supplements containing biotin may interfere in assays and may skew results to be either falsely high or falsely low. For patients receiving the recommended daily doses of biotin, draw samples at least 8 hours following the last biotin supplementation. For patients on mega-doses of biotin supplements, draw samples at least 72 hours following the last biotin supplementation.

Storage

Room Temperature

Transport Temperature

Room Temperature

Specimen Stability

  • Room Temperature: 14 days

Limitations

N/A

Other Acceptable Specimens

N/A

Unacceptable Specimens

Hemolysis

Order Code

ADP181

EPIC (Premier) Code

LAB6916

Includes

N/A

CPT Code

84393

Billing Code

670162

CPT Statement

CPT Statement

Methodology

Electrochemiluminescence (ECLIA)

FDA Status

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Physician Attestation of Informed Consent

N/A

Testing Laboratory

Quest Diagnostics Nichols Institute
33608 Ortega Highway
San Juan Capistrano CA, 92675

Department

Reference Testing

Reference Range

  •  ≤ 0.72 pg/mL

Setup Schedule / Expected Turnaround Time

Monday - Saturday; Report available: 1 - 3 days

Specimen Collection

Special Instructions

N/A

Preferred Specimen

1 mL  plasma collected in an EDTA (lavender-top) tube. Room Temperature

Minimum Volume

0.5 mL

Instructions

N/A

Patient Preparation

Dietary supplements containing biotin may interfere in assays and may skew results to be either falsely high or falsely low. For patients receiving the recommended daily doses of biotin, draw samples at least 8 hours following the last biotin supplementation. For patients on mega-doses of biotin supplements, draw samples at least 72 hours following the last biotin supplementation.

Storage

Room Temperature

Transport Temperature

Room Temperature

Specimen Stability

  • Room Temperature: 14 days

Limitations

N/A

Other Acceptable Specimens

N/A

Unacceptable Specimens

Hemolysis

Billing

CPT Code

84393

Billing Code

670162

CPT Statement

CPT Statement

Result Information

Methodology

Electrochemiluminescence (ECLIA)

Testing Laboratory

N/A

Reference Range

  •  ≤ 0.72 pg/mL

Setup Schedule / Expected Turnaround Time

Monday - Saturday; Report available: 1 - 3 days